Role of the Na+/K+/2Cl- cotransporter NKCC1 in cell cycle progression in human esophageal squamous cell carcinoma

doi:10.3748/wjg.v20.i22.6844

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 22

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6897)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-7) series, Tables (1-4) series.

Item

Count

PDF

493

WORD

365

HTML

3939

Figures (1-7)

188

Tables (1-4)

126

Sum=5111

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

869

Download

917

Sum=1786

Jun 14, 2014 (publication date) through May 2, 2024

Times Cited of This Article

Times Cited (40)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Article

World J Gastroenterol. Jun 14, 2014; 20(22): 6844-6859
Published online Jun 14, 2014. doi: 10.3748/wjg.v20.i22.6844

Role of the Na⁺/K⁺/2Cl^- cotransporter NKCC1 in cell cycle progression in human esophageal squamous cell carcinoma

Atsushi Shiozaki, Yoshito Nako, Daisuke Ichikawa, Hirotaka Konishi, Shuhei Komatsu, Takeshi Kubota, Hitoshi Fujiwara, Kazuma Okamoto, Mitsuo Kishimoto, Yoshinori Marunaka, Eigo Otsuji

Atsushi Shiozaki, Yoshito Nako, Daisuke Ichikawa, Hirotaka Konishi, Shuhei Komatsu, Takeshi Kubota, Hitoshi Fujiwara, Kazuma Okamoto, Eigo Otsuji, Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan

Mitsuo Kishimoto, Department of Pathology, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan

Yoshinori Marunaka, Departments of Molecular Cell Physiology and Bio-Ionomics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan

Yoshinori Marunaka, Japan Institute for Food Education and Health, St. Agnes’ University, Kyoto 602-8013, Japan

Author contributions: Shiozaki A and Nako Y contributed equally to this work; Shiozaki A and Nako Y designed the study, wrote the manuscript and performed the majority of the experiments; Ichikawa D, Konishi H, Komatsu S, Kubota T, Fujiwara H, Okamoto K and Kishimoto M collected and analyzed the clinicopathological data obtained from ESCC patients; Marunaka Y and Otsuji E were involved in editing the manuscript.

Supported by Grants-in-Aid for Young Scientists (B), NO. 22791295, NO. 23791557, and NO. 24791440; and a Grant-in-Aid for Scientific Research (C), NO.22591464 and NO. 24591957, from the Japan Society for the Promotion of Science

Correspondence to: Atsushi Shiozaki, Assistant Professor, Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto 602-8566, Japan. shiozaki@koto.kpu-m.ac.jp

Telephone: +81-75-2515527 Fax: +81-75-2515522

Received: October 28, 2013
Revised: January 17, 2014
Accepted: February 17, 2014
Published online: June 14, 2014

Core Tip

Core tip: The objectives of the present study were to investigate the role of Na⁺/K⁺/2Cl^- cotransporter 1 (NKCC1) in the regulation of genes involved in cell cycle progression and the clinicopathological significance of its expression in esophageal squamous cell carcinoma (ESCC). An immunohistochemical analysis revealed that the expression of NKCC1 in ESCC samples was related to the histological type. Microarray results suggested that NKCC1 exhibits marked effects on the expression of genes related to G₂/M cell cycle progression. A deeper understanding of the role of NKCC1 may lead to its use as an important biomarker and/or a novel therapeutic target for ESCC treatment.